Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
Go back to Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $161.62 | 52 Week High | $58.46 | |||
| Open | $161.62 | 52 Week Low | $31.25 | |||
| Day High | $161.62 | P/E | N/A | |||
| Day Low | $161.62 | EPS | $-0.69 | |||
| Volume | 489 | |||||
